The Medical Research Council (MRC) United Kingdom trial for childhood acute lymphoblastic leukaemia (UKALL X) randomised patients aged 0-14 years inclusive with an initial white blood count of less than 100 × 10 9 /l to receive an early intensification block, a late intensification block, both, or neither. The next trial, UKALL XI, for children aged 1-14 years, randomised between different central nervous system (CNS) directed therapies. At the beginning of the trial, all patients were also randomised between late intensification alone and both early plus late blocks. The effects of both the early and the late block in UKALL X alone have been reported previously. This paper examines the effect of the addition of the early intensification block to treatment which included late intensification, combining the data from UKALL X and the first part of UKALL XI. Early intensification was associated with fewer bone marrow relapses and a reduction in the odds of death of 0.63 (95% confidence interval: 0.46-0.87). Survival was significantly improved with an increase at 5 years of 8%, from 79 to 87%. Following this demonstration that early intensification improves survival, the effect of a third intensification block is under investigation.
Introduction
The results of treatment of acute lymphoblastic leukaemia (ALL) in childhood have steadily improved in the past 20 years. Contributing to this improvement have been increased intensity of induction, sustained chemotherapy (especially in the first few months of treatment) [1] [2] [3] and the routine use of central nervous system (CNS) directed therapy. [4] [5] [6] [7] [8] One or more periods of intensification therapy, ie the use of additional drugs, usually given by injection after achievement of remission, have also been shown to be beneficial to children with acute lymphoblastic leukaemia in all risk groups. 9 The UK Medical Research Council trial MRC UKALL X 10 for childhood ALL randomly allocated patients between an early block of intensification treatment at 5 weeks (schedule B), a late block at 20 weeks (schedule C), both (schedule D), or neither (schedule A) (Figure 1 ). Although the late intensification block was shown to be clearly beneficial, the benefit of the early block was uncertain at the time UKALL X closed in September 1990. The next trial for childhood ALL, UKALL XI, started in October 1990 and patients were randomly allocated between different CNS-directed therapies. As the effect of the early block was not yet known, all patients without CNS disease were treated with late intensification, and randomly allocated to late intensification only (C) or both early and late intensification (D). By May 1991, interim analyses showed that the addition of this early block was of benefit, and this randomisation was closed. From then on, all children were to receive both intensification blocks, and a new randomisation, to receive or not to receive a third period of intensification, was introduced in March 1992 in order to determine whether even more intensive treatment might be better. At that time the daunorubicin in induction was dropped, due to concerns about possible cardiotoxicity. The full results of UKALL X were published in 1995, 10 when the median follow-up had reached 6 years, and demonstrated that two blocks of intensification improved 5-year disease-free survival by 14% and overall survival by 11%. The benefits of intensification therapy were seen irrespective of clinical factors known to influence outcome such as age, gender and initial leucocyte count. This paper reports the additional effect of the early intensification block to treatment which included the late block, estimated from both UKALL X and UKALL XI trials combined.
Patients and methods
The UKALL X trial was open from January 1985 to September 1990 to all children aged 0-14 years with ALL, except for mature B cell ALL (surface membrane immunoglobulin positive). All patients without CNS disease and with a white blood count (WBC) under 100 × 10 9 /l were randomised between early intensification (B), late intensification (C), both (D) or neither (A) (Figure 1 ), apart from a small group of girls, aged 2-9 years and with WBC Ͻ20 × 10 9 /l, initially thought to be good risk and all allocated A during the first 3 years. The UKALL XI trial was open from October 1990 to March 1997. All patients without CNS disease, regardless of WBC, were treated with late intensification and randomised for an early block (D) or not (C). This randomisation in UKALL XI was closed at the end of May 1991 and only patients entered before that date are included in these analyses. Registration and randomisation were done centrally on computer for both trials, and randomisation was balanced within age, gender and WBC groups. weeks for those children in UKALL XI not allocated to receive cranial irradiation. The total length of treatment was 100 weeks.
All patients have been followed up to October 1996, giving a minimum follow-up of 5 years 5 months and a maximum of 11 years 10 months, except for six patients who were lost to follow-up before 5 years.
All analyses have used the logrank method 11 and were stratified by trial (UKALL X or UKALL XI), and by age, gender and WBC. The main analyses were of survival and of diseasefree survival, defined as time to relapse or death in remission but with nonremitters counted as having an event on day 1. This definition gives Kaplan-Meier curves with almost the same long-term level as event-free survival, but with the remission date displayed as the starting point of the curve. Secondary endpoints were death in remission, relapse at any site, isolated bone marrow relapse, combined bone marrow relapse, CNS relapse without bone marrow involvement and relapse at other site.
Results
In total, 729 patients were randomised between arms C and D. The numbers of patients and events in each arm are given in Table 1 for UKALL X and UKALL XI separately. The most frequent first event was isolated bone marrow relapse, of which there were 117. Fifty patients had a bone marrow relapse combined with relapse at another site, 40 had a CNS relapse without bone marrow involvement, 25 had testicular relapse, and three had isolated ocular relapse. Patients who relapsed were generally treated according to standard protocols which changed over time. There is no evidence of any difference in salvage treatment used between the two arms. In particular, 36/126 relapsing on arm C and 42/112 relapsing on arm D were entered into the UKALL R1 relapse trial, which was open from 1991 to 1995 (P = 0.1).
Ten of the 12 patients who never remitted died within 36 days of diagnosis, and one of the remission deaths in arm D occurred before intensification was started and was due to a ruptured subclavian artery caused by invasive aspergillus. Two patients survived for over 5 months on a variety of treatments but never achieved remission.
Treatment-related deaths in UKALL X have been reported in detail. 12 Among the patients randomised between C and D, none of the remission deaths was during early intensification, and only four, due to infection, were directly related to late intensification, one in arm C and three in arm D. There were no deaths in remission during treatment among the UKALL XI patients included in this report.
Of the remaining deaths in remission in UKALL X, seven were due to infection while on continuation therapy (five in arm C, two in arm D), and nine were due to other cancers (five in arm C, three in arm D), including B cell lymphoma, T cell lymphoma, chronic myeloid leukaemia, possible malignant histiocytosis, two acute myeloid leukaemia and three brain tumours.
The morbidity of the late intensification was not affected by whether the early block was given, with nearly 90% of patients experiencing some GI toxicity but only 1% at grade 3 or 4 as previously reported. Table 2 shows the results for arm D compared with arm C, after stratification by age, gender and WBC, for various endpoints. Early intensification was associated with a reduction in isolated bone marrow relapse (2P = 0.003). The effect on disease-free survival ( Figure 2 ) and relapse-free survival was non-significantly in favour of early intensification. Diseasefree survivals and 95% confidence intervals (CI) at 5 years were 62% (57.0-67.2) for C and 70% (65.4-74.8) for D, and at 10 years were 59% (53.8-64.4) for C and 66% (60.4-70.6) for D.
Generally, the prognosis of patients with bone marrow relapse is poorer than for those relapsing at other sites. [13] [14] [15] Thus the prevention of bone marrow relapses (94 in arm C, 
Discussion
The UKALL X and XI comparison of late intensification (C) vs treatment with both early and late intensification (D) showed a statistically significant reduction in isolated bone marrow relapses and improved survival due to the addition of the early intensification block. Disease-free survival and relapse-free survival were also improved, although not significantly. Other randomised trials have investigated intensification of treatment. The BFM 83 trial 16 included randomisation of a 4-week long intensification block at 22 weeks for low-risk children. This block, including dexamethasone, vincristine, doxorubicin, asparaginase, thioguanine and cytarabine, significantly improved event-free survival. In contrast, the randomisation of patients to receive or not to receive a 4-week intensification block, using prednisolone, vindesine, teniposide, ifosfamide and cytarabine, at about 13 months in the BFM 86 trial 17 did not show a significant effect of intensification on event-free survival. However, since this randomisation was restricted to intermediate-risk patients still in remission at 1 year, only 128 patients were randomised and only 23 relapses had occurred at the time of reporting. The Children's Cancer Group (CCG) 105 trial, 18 in intermediate risk childhood ALL, randomised patients in a factorial design to receive or not to receive a late intensification block given at about 15 weeks and also to either standard or intensive induction and consolidation. The late intensification block lasted 8 weeks and included vincristine, doxorubicin, asparaginase, dexamethasone, cyclophosphamide, cytarabine and thioguanine. Intensive treatment included the addition of daunorubicin to standard induction with vincristine, asparaginase and prednisolone and used cyclophosphamide and cytarabine with mercaptopurine, rather than vincristine with mercaptopurine, for consolidation. The late intensification block significantly improved event-free survival at 5 years while the intensive induction/consolidation had only a slight, nonsig-
Figure 2
Disease-free survival in UKALL X and UKALL XI combined for those patients randomised to late intensification alone (C) or both intensification blocks (D).
Figure 3
Survival in UKALL X and UKALL XI combined for those patients randomised to late intensification alone (C) or both intensification blocks (D). nificant advantage over the standard induction/consolidation. Although the effect of late intensification was not significant in this CCG trial in patients 10 years old or over, this is a subgroup analysis, with low statistical power due to the reduced numbers, and likely to be due to chance. Neither of these trials has reported results for these randomisations in terms of survival or of relapse at different sites, but the results are consistent with the idea that giving one or two intensive blocks of treatment post-induction is beneficial. The question of whether a third, BFM type, intensive block later in treatment adds further benefit is being addressed by the current MRC trials (UKALL XI92 and ALL97).
Although the intensification blocks had short-term toxicity, as measured by the use of antibiotics and amphotericin and the occurrence of serious GI toxicity, 10 there is no evidence that the early block increased treatment-related deaths, either from infection or from secondary tumours. So far, long-term studies of secondary malignancies after treatment for childhood ALL [19] [20] [21] show that the incidence is low, under 5%, and is at least partly related to irradiation and/or additional treatment given for relapse. With the decreasing use of irradiation and fewer relapses, the risk of secondary tumours may be reduced despite the increased intensity of chemotherapy. Anthracycline-induced cardiotoxicity is also a concern [22] [23] [24] and daunorubicin was dropped from induction when the UKALL XI protocol was modified in 1992. Studies so far have not found clinically evident cardiac problems in patients treated with doses of 270 mg/m 2 or less as they were in UKALL X and UKALL XI. All MRC trial patients are monitored longterm for the occurrence of secondary tumours and clinical evidence of any serious cardiotoxicity, and these will be reported in due course.
In conclusion, the addition to standard treatment for childhood ALL of a second short block of intensive treatment given soon after induction prevented bone marrow relapses and increased survival by about 8% at 5 years, even among patients receiving a similar intensification block at 20 weeks. The effect of further intensification of treatment is worthy of investigation, and this is one of the questions being addressed by the current MRC ALL trial.
